Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Merger or Acquisition (December 2006)
8 slides from Mayne Pharma's merger presentation, Dec 20, 2006
Slide 1: Please ensure that your mobile phone is switched OFF
Please ensure that your mobile phone is switched OFF
Slide 2: Mayne Pharma Limited Extraordinary General Meeting
Mayne Pharma Limited Extraordinary General Meeting 20 December 2006 Melbourne, Australia
Slide 3: Value creation
Value creation Value of Mayne Group share prior to $3.53 demerger Value of Mayne Pharma share at $4.10 Hospira offer price Value of Symbion share at close of + $3.64 business on Tuesday 19 December Total $7.74 +119%
Slide 4: Reasons to approve the scheme
Reasons to approve the scheme • Significant premium • Favourable implied earnings multiple • Certain and immediate value • Towards the top end of the independent expert’s value range • In the best interests of Mayne Pharma shareholders
Slide 5: Timetable to closing
Timetable to closing Event Time and date Court hearing for approval of the Tuesday 16 January 2007 Scheme Effective Date Wednesday 17 January 2007 Suspension of trading in Mayne Close of trading on Wednesday 17 Pharma shares on ASX January 2007 7.00 pm on Wednesday 24 January Record Date 2007 Implem
Slide 6: Resolution
Resolution • “That pursuant to, and in accordance with, section 411 of the Corporations Act, the scheme meeting of arrangement proposed between the company and the holders of its ordinary shares as contained in and more particularly described in the Explanatory Memorandum is approved (with or withou
Slide 7: Resolution: proxy results
Resolution PROXY RESULTS Number of shares Percentage Votes For 313,253,722 97.47% Votes Against 2,734,167 0.85% Discretionary* 5,410,562 1.68% TOTAL 321,398,451 100% * The number of the Chairman’s discretionary proxy votes are 4,632,479 (1.44%) Note: These figures relate to the proxies lodged 48 hou
Slide 8: Mayne Pharma Limited Extraordinary General Meeting 2006
Mayne Pharma Limited Extraordinary General Meeting 2006